#USA #Boston #GEMMABio #Duchenne Muscular Dystrophy #spinal muscular atrophy

GEMMABio Unveils Innovative Gene Therapies

During the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, GEMMA Biotherapeutics, widely known as GEMMABio, introduced groundbreaking findings about their innovative gene therapies targeted at Duchenne muscular dystrophy (DMD) and Spinal muscular atrophy type 1 (SMA1). The presentation included detailed preclinical data on two investigational candidates: GB703 for DMD and GB221 for SMA1.

DMD is a severe genetic disorder caused by mutations in the dystrophin gene, ultimately leading to progressive muscle degeneration, primarily affecting young boys. In contrast, SMA1 is a devastating neurological condition impacting motor neurons, causing severe muscular weakness and impairing essential life functions.

Key Features of GB703 for DMD

Broadening Mutation Coverage

GEMMABio's GB703 is constructed using a novel AAV (adeno-associated virus) capsid designed to enhance delivery efficiency and broaden the treatment scope. The micro-utro/dystrophin hybrid gene is meant to address a variety of dystrophin mutations through its de-immunized transgene design. Notably, this innovative design aims to improve safety and minimize immune response risks in patients.

Novel Capsid Design

The engineered AAV capsid, designated GCap104, refined for its myotropic properties, effectively targets skeletal and heart muscles, providing a tailored approach for DMD patients. Preclinical studies revealed that this new capsid managed to express the hybrid micro-utro/dystrophin gene successfully in nonhuman primates at low dosing levels.

Successful Outcomes in Animal Models

The promising results from trials with GB703 indicated measurable biological benefits, such as restoration of critical muscle complexes and a noticeable reduction in muscle damage indicators in a mouse model designed to mimic DMD.

Highlights of GB221 for SMA1

Innovative AAV Design

In their SMA1 program, GEMMABio presented the GB221 treatment, which integrates unique microRNA target technology. This revolutionary treatment aims to facilitate SMN1 (survival motor neuron 1) expression specifically in motor neurons while mitigating the risk of sensory neuron toxicity, a common concern with therapies that impact the dorsal root ganglia.

Promising Preclinical Results

Animal studies demonstrated exceptional outcomes, showing a marked improvement in survival rates and motor function for treated SMA1 mice compared to untreated ones. Specifically, over 50% of transgenic mice survived until 120 days post-treatment, while untreated controls showed significantly lower survival rates.

Safety Profile

Administration via intra-cisterna magna injection proved safe, with no adverse effects such as liver toxicity or cardiac complications observed in nonhuman primates, allowing for high transgene expression without associated negative impacts.

Moving Forward

With both GB703 and GB221 promising advanced therapeutic options for patients grappling with DMD and SMA1, GEMMABio continues to evolve its programs towards clinical trials. As stated by Dr. Juliette Hordeaux, Chief Scientific Officer at GEMMABio, the company's vision emphasizes safety, efficacy, and equitable access, ensuring that the gene therapies developed address both medical needs and enhance patient quality of life.

Conclusion

GEMMABio’s relentless pursuit of innovative gene therapies for DMD and SMA1 marks an important milestone in genetic medicine. As they advance through regulatory hurdles and approach clinical trial phases, the scientific community looks forward to seeing how these novel therapies could potentially transform the management and treatment landscape for these devastating conditions.